Syndax Pharmaceuticals GAAP EPS of -$0.78 misses by $0.23, revenue of $68.7M beats by $3.95M
Source: SeekingAlpha
2026-02-26 16:38:18 ET
More on Syndax Pharmaceuticals
- Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026
- Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Syndax Pharmaceuticals, Inc. (SNDX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Syndax Pharmaceuticals Q4 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Syndax Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Syndax Pharmaceuticals GAAP EPS of -$0.78 misses by $0.23, revenue of $68.7M beats by $3.95M
Syndax Pharmaceuticals Inc.
NASDAQ: SNDX
SNDX Trading
-4.52% G/L:
$23.775 Last:
469,416 Volume:
$24.01 Open:
SNDX Latest News
February 26, 2026 04:01:00 pm
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
SNDX Stock Data
$1,884,313,688
83,351,330
1.17%
104
N/A
Biotechnology & Life Sciences
Healthcare
US
NEW YORK
